# A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

> **NCT01991678** · PHASE1 · COMPLETED · sponsor: **Nektar Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

## Interventions

- **DRUG:** 145 mg/m2 NKTR 102
- **DRUG:** 120 mg/m2 NKTR 102
- **DRUG:** 50 mg/m2 NKTR 102

## Key facts

- **NCT ID:** NCT01991678
- **Lead sponsor:** Nektar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2017-05
- **Final completion:** 2017-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01991678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01991678, "A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01991678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*